CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Blueprint Medicines Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Blueprint Medicines Corp
45 Sidney Street
Phone: (617) 374-7580p:617 374-7580 CAMBRIDGE, MA  02139  United States Ticker: BPMCBPMC
Business Summary
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Jeffrey W.Albers 52 12/31/2022 7/1/2014
President, Chief Executive Officer, Director Kathryn D.Haviland 48 4/4/2022 1/5/2016
Chief Financial Officer MichaelLandsittel 52 1/30/2019 9/1/2014
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Blueprint Medicines (France) SAS
Blueprint Medicines (Italy) S.r.L.
Blueprint Medicines (Netherlands) B.V.
5 additional Business Names available in full report.

General Information
Number of Employees: 649 (As of 1/31/2025)
Outstanding Shares: 63,906,011 (As of 2/11/2025)
Shareholders: 7
Stock Exchange: NASD
Federal Tax Id: 263632015
Fax Number: (302) 655-5049
Email Address: info@blueprintmedicines.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 16, 2025